Tyra Biosciences (TYRA) Accumulated Expenses (2020 - 2026)

Tyra Biosciences (TYRA) has 7 years of Accumulated Expenses data on file, last reported at $2.0 million in Q1 2026.

• Quarterly Accumulated Expenses rose 30.31% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 30.31% YoY) and the FY2025 annual result came in at $5.5 million, down 14.23% from the prior year.
• Accumulated Expenses retreated to $2.0 million in Q1 2026, from $5.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $6.5 million in Q4 2024 to a low of $863000.0 in Q1 2023.
• A 5-year average of $2.6 million and a median of $2.2 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 123.32% — and 2025, when it fell 18.19%.
• Tracing TYRA's Accumulated Expenses over 5 years: stood at $2.9 million in 2022, then surged by 79.29% to $5.1 million in 2023, then rose by 26.07% to $6.5 million in 2024, then slipped by 14.23% to $5.5 million in 2025, then plunged by 63.64% to $2.0 million in 2026.
• The last three Accumulated Expenses figures came in at $2.0 million (Q1 2026), $5.5 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.